0.4505

2.68% -0.0124

Atyr Pharma Inc (ATYR)

Overview News Price History Discussions Forecast

Atyr Pharma Inc stock is traded at $0.4505, with a volume of 1.53M. It is down -2.68% in the last 24 hours and down -13.28% over the past month. aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Previous Close:

$0.4629

Open:

$0.4762

24h Volume:

1.53M

Relative Volume:

0.71

Market Cap:

$44.17M

Revenue:

$190.00K

Net Income/Loss:

$-70.03M

P/E Ratio:

-0.6135

EPS:

-0.7343

Net Cash Flow:

$-59.30M

1W Performance:

-5.24%

1M Performance:

-13.28%

6M Performance:

-35.93%

1Y Performance:

-91.29%

1-Day Range:

$0.4501

$0.4883

1-Week Range:

$0.44

$0.4972

52-Week Range:

$0.395

$7.2904

Atyr Pharma Inc Stock (ATYR) Company Profile

Name

Atyr Pharma Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

(858) 731-8389

Address

10240 SORRENTO VALLEY ROAD, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

ATYR's Discussions on Twitter

Compare ATYR vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATYR Atyr Pharma Inc	0.4505	44.17M	190.00K	-70.03M	-59.30M	-0.7343
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-16-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-15-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-15-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-15-25	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-18-25	Initiated	Leerink Partners	Outperform
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Oct-04-24	Initiated	Wells Fargo	Overweight
Sep-05-24	Initiated	Jefferies	Buy
Jul-05-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-12-21	Initiated	RBC Capital Mkts	Outperform
Sep-21-21	Initiated	Piper Sandler	Overweight
May-10-21	Initiated	Laidlaw	Buy
Aug-17-20	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-04-20	Initiated	ROTH Capital	Buy
Mar-02-20	Initiated	Oppenheimer	Outperform
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-07-17	Initiated	Piper Jaffray	Overweight
Dec-13-16	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-15	Initiated	Citigroup	Neutral
Jun-01-15	Initiated	Citigroup	Buy
Jun-01-15	Initiated	JP Morgan	Overweight

View All

Atyr Pharma Inc Stock (ATYR) Latest News

Jun 18, 2026

aTyr Pharma Ord Shs (LIFE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 18, 2026

Jun 17, 2026